{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Talia M"],"funding":["Ministero dell'Università e della Ricerca","Ministero della Salute","Fondazione AIRC per la ricerca sul cancro ETS","Ministero dell’Università e della Ricerca"],"pagination":["597"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11210052"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["<h4>Background</h4>Over the last two decades, tumor-derived RNA expression signatures have been developed for the two most commonly diagnosed tumors worldwide, namely prostate and breast tumors, in order to improve both outcome prediction and treatment decision-making. In this context, molecular signatures gained by main components of the tumor microenvironment, such as cancer-associated fibroblasts (CAFs), have been explored as prognostic and therapeutic tools. Nevertheless, a deeper understanding of the significance of CAFs-related gene signatures in breast and prostate cancers still remains to be disclosed.<h4>Methods</h4>RNA sequencing technology (RNA-seq) was employed to profile and compare the transcriptome of CAFs isolated from patients affected by breast and prostate tumors. The di"],"journal":["Journal of translational medicine"],"pubmed_title":["Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients."],"pmcid":["PMC11210052"],"funding_grant_id":["IG n. 23369","Start-Up Grant 21651","Prin 2022 PNRR P2022MALRP","IG n. 27386","Prin 2022 202282CMEA","RF-2019-12368937","Prin 2022 2022Y79PT4"],"pubmed_authors":["Cirillo F","Cesario E","Mondino AA","Talia M","Belfiore A","Miglietta AM","Occhiuzzi MA","Di Dio M","Scordamaglia D","Capalbo C","Zicarelli A","Lappano R","De Francesco EM","Maggiolini M"],"additional_accession":[]},"is_claimable":false,"name":"Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients.","description":"<h4>Background</h4>Over the last two decades, tumor-derived RNA expression signatures have been developed for the two most commonly diagnosed tumors worldwide, namely prostate and breast tumors, in order to improve both outcome prediction and treatment decision-making. In this context, molecular signatures gained by main components of the tumor microenvironment, such as cancer-associated fibroblasts (CAFs), have been explored as prognostic and therapeutic tools. Nevertheless, a deeper understanding of the significance of CAFs-related gene signatures in breast and prostate cancers still remains to be disclosed.<h4>Methods</h4>RNA sequencing technology (RNA-seq) was employed to profile and compare the transcriptome of CAFs isolated from patients affected by breast and prostate tumors. The di","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jun","modification":"2026-06-02T01:48:54.271Z","creation":"2026-04-13T03:12:15.495Z"},"accession":"S-EPMC11210052","cross_references":{"pubmed":["38937754"],"doi":["10.1186/s12967-024-05413-2"]}}